A phase I, open-label, multi-center, dose escalation study of oral NVP-CGM097, a p53/HDM2-protein-protein interaction inhibitor, in adult patients with selected advanced solid tumors

被引：6
|
作者：
Bauer, S. [1 ]
Demetri, G. [2 ]
Jeay, S. [3 ]
Dummer, R. [4 ]
Guerreiro, N. [3 ]
Tan, D. S. [5 ]
Kumar, A. [6 ]
Meille, C. [3 ]
Van Bree, L. [3 ]
Halilovic, E. [7 ]
Wuerthner, J. U. [3 ]
Cassier, P. [8 ]
机构：
[1] Univ Klinikum Essen, Internal Med, Essen, Germany
[2] Dana Farber Canc Inst, Ludwig Ctr, Boston, MA 02115 USA
[3] Novartis Pharma AG, Basel, Switzerland
[4] Univ Zurich Hosp, Zurich, Switzerland
[5] Natl Canc Ctr, Singapore, Singapore
[6] Novartis Healthcare Pvt Ltd, Hyderabad, Andhra Pradesh, India
[7] Novartis Inst BioMed Res, Cambridge, MA USA
[8] Ctr Leon Berard, Lyon, France
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
10.1093/annonc/mdw368.9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
366PD
引用
收藏
页数：1
相关论文
共 50 条
  • [31] A Phase I, open-label, dose escalation study of afatinib, in a 3-week-on/1-week-off schedule in patients with advanced solid tumors
    John Marshall
    Jimmy Hwang
    Ferry A. L. M. Eskens
    Herman Burger
    Shakun Malik
    Martina Uttenreuther-Fischer
    Peter Stopfer
    Mahmoud Ould-Kaci
    Roger B. Cohen
    Nancy L Lewis
    Investigational New Drugs, 2013, 31 : 399 - 408
  • [32] Phase I, open-label, dose-escalation study of AZD7762 in combination with irinotecan (irino) in patients (pts) with advanced solid tumors.
    Ho, A. L.
    Bendell, J. C.
    Cleary, J. M.
    Schwartz, G. K.
    Burris, H. A.
    Oakes, P.
    Agbo, F.
    Barker, P. N.
    Senderowicz, A. M.
    Shapiro, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [33] A Phase I, open-label, dose escalation study of afatinib, in a 3-week-on/1-week-off schedule in patients with advanced solid tumors
    Marshall, John
    Hwang, Jimmy
    Eskens, Ferry A. L. M.
    Burger, Herman
    Malik, Shakun
    Uttenreuther-Fischer, Martina
    Stopfer, Peter
    Ould-Kaci, Mahmoud
    Cohen, Roger B.
    Lewis, Nancy L.
    INVESTIGATIONAL NEW DRUGS, 2013, 31 (02) : 399 - 408
  • [34] A phase I, open-label, multicenter, dose escalation and expansion study of HM97662 (EZH1/2 dual inhibitor) as a single agent in patients with advanced or metastatic solid tumors
    Keam, B.
    Ahn, J-H.
    Kim, K.
    Hong, S-H.
    Ganju, V.
    Lim, L. E.
    Kwatra, V.
    Body, A.
    Rhee, P. D.
    Jung, S.
    Yoon, J.
    Baek, E.
    Noh, Y. S.
    ANNALS OF ONCOLOGY, 2024, 35 : S532 - S532
  • [35] Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors
    Desai, Jayesh
    Gan, Hui
    Barrow, Catherine
    Jameson, Michael
    Atkinson, Victoria
    Haydon, Andrew
    Millward, Michael
    Begbie, Stephen
    Brown, Michael
    Markman, Ben
    Patterson, William
    Hill, Andrew
    Horvath, Lisa
    Nagrial, Adnan
    Richardson, Gary
    Jackson, Christopher
    Friedlander, Michael
    Parente, Phillip
    Tran, Ben
    Wang, Lai
    Chen, Yunxin
    Tang, Zhiyu
    Huang, Wendy
    Wu, John
    Zeng, Dewan
    Luo, Lusong
    Solomon, Benjamin
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (19) : 2140 - +
  • [36] An open-label, multi-center phase I study of the safety and tolerability of the novel immunomodulatory agent PG545 in subjects with advanced solid tumors.
    Dredge, Keith
    Brennan, Todd
    Brown, Michael Paul
    Lickliter, Jason D.
    Barnpton, Darryn
    Hammond, Edward
    Lin, Liwen
    Yang, Yiping
    Millward, Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [37] A First-in-Human, Open-Label, Phase I Dose Escalation Trial of Daily Oral Nmt Inhibitor Zelenirstat in Patients with Relapsed/Refractory B-Cell Lymphomas and Advanced Solid Tumors
    Sangha, Randeep
    Jamal, Rahima
    Spratlin, Jennifer
    Kuruvilla, John
    Sehn, Laurie H.
    Weickert, Michael
    Berthiaume, Luc
    Mackey, John Robert
    BLOOD, 2023, 142
  • [38] ONX 0912, a Novel Oral Proteasome Inhibitor (PI), In Patients (pts) With Advanced Refractory or Recurrent Solid Tumours: a Phase 1, Open-label, Dose Escalation Study
    Papadopoulos, K.
    Mendelson, D.
    Tolcher, A. W.
    Burris, H. A.
    Gordon, M.
    Wong, H.
    Bomba, D.
    Lee, S.
    Gillenwater, H.
    Infante, J.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S147 - S147
  • [39] Safety, Tolerability, and Preliminary Activity of LB-100, an Inhibitor of Protein Phosphatase 2A, in Patients with Relapsed Solid Tumors: An Open-Label, Dose Escalation, First-in-Human, Phase I Trial
    Chung, Vincent
    Mansfield, Aaron S.
    Braiteh, Fadi
    Richards, Donald
    Durivage, Henry
    Ungerleider, Richard S.
    Johnson, Francis
    Kovach, John S.
    CLINICAL CANCER RESEARCH, 2017, 23 (13) : 3277 - 3284
  • [40] A phase I, open-label, multicenter dose escalation study to assess the safety, tolerability, and pharmacokinetics of AZD2811 nanoparticle in patients with advanced solid tumors.
    Johnson, Melissa Lynne
    Wang, Judy Sing-Zan
    Falchook, Gerald Steven
    Charlton, Julie
    MacDonald, Alexander
    Strickland, Donald
    Jones, Suzanne Fields
    Pease, Elizabeth J.
    Brugger, Wolfram
    Burris, Howard A.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345